Clinical Trials List
2020-05-29 - 2025-06-12
Phase III
Recruiting1
Terminated8
The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT).
-
Trial Applicant
ELI LILLY AND COMPANY(TAIWAN), INC.
-
Sponsor
Eli Lilly and Company
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 蔡易婷 Division of Endocrinology
- 鄭由承 Division of Endocrinology
- 梁凱偉 Division of Cardiovascular Diseases
- 許惠恒 Division of Endocrinology
- 傅家保 Division of Endocrinology
- JUN-SING WANG Division of Endocrinology
- 張之昀 Division of Endocrinology
- 沈宜靜 Division of Endocrinology
- 李宇璇 Division of Endocrinology
- 陳彥銘 Division of Endocrinology
- 王奇彥 Division of Cardiovascular Diseases
- 林時逸 Division of Geriatrics
- 李佳霖 Division of Endocrinology
- 陳威麟 Division of Endocrinology
- Yu-Cheng Hsieh Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wen-Chung Yu Division of Cardiovascular Diseases
- 吳承學 Division of General Internal Medicine
- 陳涵栩 Division of Endocrinology
- Chern-En Chiang 醫學研究部
- Harn-Shen Chen Division of Endocrinology
- Tse-Min Lu Division of Family Medicine
- Hao-min Cheng 教學部
- 陳涵栩 Division of Endocrinology
- Kang-Ling Wang 醫學研究部
- 黃少嵩 Division of Family Medicine
- Chin-Sung Kuo Division of Endocrinology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 李文煌 Division of Cardiovascular Diseases
- Po-Sheng Chen Division of Cardiovascular Diseases
- Hao-Chang Hung Division of Endocrinology
- Po-Tseng Lee Division of Cardiovascular Diseases
- Yen-Wen Liu Division of Cardiovascular Diseases
- 林景翰 Division of Endocrinology
- Cheng-Han Lee Division of Cardiovascular Diseases
- 陳柏偉 Division of Cardiovascular Diseases
- 杜業豐 Division of Endocrinology
- 林志展 Division of Cardiovascular Diseases
- Horng-Yih Ou Division of Endocrinology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
2. Have confirmed atherosclerotic cardiovascular disease
3. HbA1c ≥7.0% to ≤10.5%
4. Body mass index (BMI) ≥25 kilograms per meter squared (kg/m²)
Exclusion Criteria
2.Have type 1 diabetes mellitus
3.Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the last 6 months
4.Are currently planning treatment for diabetic retinopathy and/or macular edema
5.Currently planning a coronary, carotid, or peripheral artery revascularization
6.Have a history of pancreatitis
7.Have a history of ketoacidosis or hyperosmolar state/coma
8.Have a known clinically significant gastric emptying abnormality, have undergone or currently planning any gastric outlet obstruction, or have undergone or currently planning any gastric bypass (bariatric) surgery or restrictive bariatric surgery
9.Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
10.Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
11.Have had a blood transfusion or severe blood loss within 90 days prior to screening or have known hematological conditions that may interfere with HbA1c measurement
The Estimated Number of Participants
-
Taiwan
180 participants
-
Global
13299 participants
